Abstract
ABSTRACTIntroduction: On 18 September 2012, United States health officials began to react to a large outbreak of fungal meningitis traceable to methylprednisolone from a compounding pharmacy in Framingham, Massachusetts. Although the index case was attributed to the opportunistic mold Aspergillus fumigatus, all subsequent cases were due to the dematiaceous mold Exserohilum rostratum, which had previously been an uncommon cause of disease in humans.Areas covered: In this paper, the authors examine recent advances in the diagnosis and treatment of Exserohilum infection and provide updates on how the innate and acquire immune responses enable clearance of human fungal pathogens.Expert commentary: The fungal meningitis outbreak of 2012 stretched across 20 states and resulted in 753 cases of central nervous system infection and 64 deaths. In this paper, the authors examine how the outbreak prompted investigators to develop novel diagnostic and therapeutic options that have advanced the study of human fungal pathogens and will benefit patients who are susceptible to invasive mycoses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Expert Review of Precision Medicine and Drug Development
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
